Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Impact of increased drug availability on acute leukemia

Oliver Ottmann • 3 Jul 2020
ESH AL 2020
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Venetoclax

A higher number of drugs available as potential treatment options for leukemia means that there has to be increased opportunity for testing, trials and higher patient numbers. Oliver Ottmann, MD, FRCPath, University of Cardiff, Cardiff, UK, talks about the importance of trials and combination drug therapy when treating acute leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Oliver Ottmann

Molecular profiling to determine treatment for ALL and AML
3:24
Molecular profiling to determine treatment for ALL and AML
Oliver Ottmann • 3 Jul 2020
How age as a prognostic factor affects treatment options for ALL
3:07
How age as a prognostic factor affects treatment options for ALL
Oliver Ottmann • 3 Jun 2020
Treatment options for Ph+ ALL
5:23
Treatment options for Ph+ ALL
Oliver Ottmann • 3 Jul 2020
The evolving landscape of ALL therapy and the impact of MRD
15:02
The evolving landscape of ALL therapy and the impact of MRD
Dieter Hoelzer et al. • 17 May 2019

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals